Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Trevi Therapeutics (Nasdaq: TRVI) will report its fourth quarter and year‑end 2025 financial results and provide business updates on March 17, 2026 at 4:30 p.m. ET.

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) will report its fourth quarter and year‑end 2025 financial results and provide business updates on March 17, 2026 at 4:30 p.m. ET. Senior management will host a conference call and live audio webcast to review results and corporate developments.

Investors can register via the company website at ir.trevitherapeutics.com/news-events/events; registered phone participants receive unique call‑in details by email. An archived replay will be available for 30 days after the event.

Argus Mar 11 session

+1.53% close to close Open Argus

Details

News Market Reaction – TRVI

On Mar 11, the first trading day after this news, TRVI closed 1.53% above the previous close.

Data tracked by StockTitan Argus for the Mar 11 session.

Market Context

This announcement schedules Trevi’s March 17, 2026 call to review Q4 and full-year 2025 results and ...

Analysis

This announcement schedules Trevi’s March 17, 2026 call to review Q4 and full-year 2025 results and provide business updates on Haduvio. In recent months, the company reported Phase 2b JAMA data and End-of-Phase 2 FDA alignment for two planned Phase 3 trials. Investors may watch this call for clarity on development timelines, resource allocation, and how the late-stage program shapes Trevi’s financial and strategic outlook.

Key Figures

Share price: $11.70 Daily change: -12.03% Today’s volume: 1,859,609 shares +5 more

Share price

$11.70

TRVI pre-news context price

Daily change

-12.03%

24-hour price change before this earnings-date news

Today’s volume

1,859,609 shares

Trading volume on news day

20-day avg volume

1,288,517 shares

Average trading volume over last 20 days

52-week high

$14.39

Pre-news 52-week high level

52-week low

$4.24

Pre-news 52-week low level

Earnings call time

4:30 p.m. ET

Q4 and year-end 2025 results call on March 17, 2026

Webcast replay window

30 days

Archived replay availability on company website

Previous Earnings date Reports

1 past event · Latest: Nov 06

Same Type 1 event

1. Nov 06

   Earnings call scheduling

   24h Move

   +0.0%

   Announcement of Q3 2025 results call and corporate update timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough

3 terms

idiopathic pulmonary fibrosis medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC)"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. 

Conference Call and Webcast
To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.     
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.    

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.   

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.  
  
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.  

Investor Contact   
Jonathan Carlson   
Trevi Therapeutics, Inc.   
(203) 654 3286   
IR@trevitx.com

Media Contact   
Rosalia Scampoli   
914-815-1465   
rscampoli@marketcompr.com    

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Trevi Therapeutics (TRVI) report Q4 and year‑end 2025 results and host the webcast?

Trevi Therapeutics will report results and host a webcast on March 17, 2026 at 4:30 p.m. ET. According to the company, senior management will provide business updates and review fourth quarter and year‑end 2025 financial results.

How can investors register for the Trevi Therapeutics (TRVI) conference call and webcast on March 17, 2026?

Investors can register at ir.trevitherapeutics.com/news-events/events to join the live call or webcast. According to the company, phone registrants will receive an email with unique call‑in details after registering.

Will Trevi Therapeutics (TRVI) provide a replay of the March 17, 2026 webcast and for how long?

Yes. An archived replay of the webcast will be available for 30 days after the event on the company website. According to the company, the replay will be accessible in the Investors & News section following the live presentation.

What topics will Trevi Therapeutics (TRVI) cover during the March 17, 2026 conference call?

The call will review the company's fourth quarter and year‑end 2025 financial results and provide business updates. According to the company, senior management will discuss corporate developments and progress on its investigational therapy Haduvio.

Can shareholders access the Trevi Therapeutics (TRVI) March 17, 2026 event via phone if they cannot join the webcast?

Yes. Registered phone participants receive unique call‑in details by email to join the live conference call. According to the company, phone access is available after registration on the investor events page.